Baird Medical Investment Holdings Limited

AI-generated fair value estimate for this company.

Method: 10-year revenue-and-margin-ramp DCF: revenue base $24.49M (down 23% year over year) assumed flat in year 1 then recovering 5-8% in years 2-5 and 5-7% in years 6-10; FCF margin improving from roughly -5% to +15% as scale and mix improve; 12% discount rate; 3% terminal growth; approximately $3M estimated net cash; 42.21M shares outstanding.

Reasoning: Baird Medical's China-concentrated microwave-ablation device revenue has recently declined, likely reflecting local pricing/reimbursement pressure, so the model assumes a trough-and-recovery revenue path rather than immediate resumed growth; the higher discount rate reflects China regulatory, currency, and small-cap ADS risk.